How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,163 results for

Kaposis Sarcoma

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

2. Kaposi's sarcoma

Kaposi's sarcoma Kaposi's sarcoma - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Kaposi's sarcoma Last reviewed: February 2019 Last updated: June 2018 Summary A low-grade vasoformative neoplasm that is associated with human herpesvirus-8 (HHV-8) or Kaposi's sarcoma herpesvirus (KSHV) infection. There are 4 main subtypes of Kaposi's sarcoma: epidemic AIDS-related; classic sporadic; iatrogenic and transplant (...) -associated; and African endemic. Patients may present with multifocal cutaneous lesions, mucosal lesions, or lymph node or visceral involvement. Therapy is given for symptom palliation, to prevent disease progression, and for cosmetic reasons. Definition Kaposi's sarcoma (KS) is a low-grade vasoformative neoplasm associated with human herpesvirus-8 (HHV-8) or Kaposi's sarcoma herpesvirus (KSHV) infection. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS

2018 BMJ Best Practice

3. A fifth subtype of Kaposi's sarcoma, classic Kaposi's sarcoma in men who have sex with men: a cohort study in Paris. (PubMed)

A fifth subtype of Kaposi's sarcoma, classic Kaposi's sarcoma in men who have sex with men: a cohort study in Paris. Classic Kaposi's sarcoma (CKS) occurs predominantly among elderly men and is associated with Kaposi's sarcoma-associated herpesvirus (KSHV). In low-endemic countries, KSHV infects predominantly men having sex with men (MSM).To describe a cohort of classic Kaposi sarcoma in a low-endemic area for KSHV, to highlight the features of CKS in MSM and identify prognostic

2018 Journal of the European Academy of Dermatology and Venereology

4. Diabetes and risk of Kaposi's sarcoma: effects of high glucose on reactivation and infection of Kaposi's sarcoma-associated herpesvirus (Full text)

Diabetes and risk of Kaposi's sarcoma: effects of high glucose on reactivation and infection of Kaposi's sarcoma-associated herpesvirus Patients with diabetes are generally prone to pathogen infection and tumor progression. Here, we investigated the potential association between diabetes and Kaposi's sarcoma (KS), a tumor linked to infection with Kaposi's sarcoma-associated herpesvirus (KSHV). By using Taiwan's National Health Insurance Research Database, we found that diabetes is statistically

2017 Oncotarget PubMed

5. Epigenetic Landscape of Kaposi's Sarcoma-Associated Herpesvirus Genome in Classic Kaposi's Sarcoma Tissues (Full text)

Epigenetic Landscape of Kaposi's Sarcoma-Associated Herpesvirus Genome in Classic Kaposi's Sarcoma Tissues Kaposi's sarcoma-associated herpesvirus (KSHV) is etiologically related to Kaposi's sarcoma (KS), primary effusion lymphoma (PEL) and multicentric Castleman's disease (MCD). It typically displays two different phases in its life cycle, the default latency and occasional lytic replication. The epigenetic modifications are thought to determine the fate of KSHV infection. Previous studies

2017 PLoS pathogens PubMed

6. Health-Related Quality of Life in Patients Treated With Antiretroviral Therapy Only Versus Chemotherapy and Antiretroviral Therapy for HIV-Associated Kaposi Sarcoma: A Randomized Control Trial. (Full text)

Health-Related Quality of Life in Patients Treated With Antiretroviral Therapy Only Versus Chemotherapy and Antiretroviral Therapy for HIV-Associated Kaposi Sarcoma: A Randomized Control Trial. In sub-Saharan Africa, Kaposi sarcoma (KS) is the most common HIV-associated cancer. KS causes substantial morbidity, and treatment goals should emphasize quality of life (QOL). Antiretroviral therapy (ART) is indicated, and early chemotherapy significantly improves tumor regression. The effect of ART (...) alone or with chemotherapy on QOL in treatment-naïve South Africans with HIV-associated KS was assessed.KAART (Kaposi Sarcoma AIDS Anti-Retroviral Therapy) is a randomized, controlled, open-label trial of ART versus ART plus chemotherapy. Crossover between arms was allowed for patients with progressive disease. Eighty-nine percent of patients had advanced tumor burden. Within KAART, QOL measured by European Organization for Research and Treatment of Cancer-QLQ-C30 questionnaire evaluated functional

2018 Journal of global oncology PubMed

7. Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults. (Full text)

Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults. Kaposi's sarcoma remains the most common cancer in Sub-Saharan Africa and the second most common cancer in HIV-infected patients worldwide. Since the introduction of highly active antiretroviral therapy (HAART), there has been a decline in its incidence.However, Kaposi's sarcoma continues to be diagnosed in HIV-infected patients.To assess the added advantage of chemotherapy plus HAART compared to HAART alone (...) and three observational studies involving 792 HIV-infected adults with severe Kaposi's sarcoma.Seven studies included patients with a mix of mild to moderate (T0) and severe (T1) Kaposi's sarcoma. However, this review was restricted to the subset of participants with severe Kaposi's sarcoma disease.Studies comparing HAART plus chemotherapy to HAART alone showed the following: one trial comparing HAART plus doxorubicin,bleomycin and vincristine (ABV) to HAART alone showed a significant reduction

2014 Cochrane PubMed

8. Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults. (Full text)

Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults. Background Kaposi's sarcoma remains the most common cancer in Sub-Saharan Africa and the second most common cancer in HIV-infected patients worldwide. Since the introduction of highly active antiretroviral therapy (HAART), there has been a decline in its incidence.However, Kaposi's sarcoma continues to be diagnosed in HIV-infected patients.Objectives To assess the added advantage of chemotherapy plus HAART compared (...) trials assessed identical chemotherapy regimens.Main results We included six randomised trials and three observational studies involving 792 HIV-infected adults with severe Kaposi's sarcoma.Seven studies included patients with a mix of mild to moderate (T0) and severe (T1) Kaposi's sarcoma. However, this review was restricted to the subset of participants with severe Kaposi's sarcoma disease.Studies comparing HAART plus chemotherapy to HAART alone showed the following: one trial comparing HAART plus

2014 Cochrane PubMed

9. Proposal of a Risk-Stratification Platform to Address Distinct Clinical Features of Pediatric Kaposi Sarcoma in Lilongwe, Malawi (Full text)

Proposal of a Risk-Stratification Platform to Address Distinct Clinical Features of Pediatric Kaposi Sarcoma in Lilongwe, Malawi 29272148 2019 03 04 2378-9506 4 2018 Sep Journal of global oncology J Glob Oncol Proposal of a Risk-Stratification Platform to Address Distinct Clinical Features of Pediatric Kaposi Sarcoma in Lilongwe, Malawi. 1-7 10.1200/JGO.17.00054 El-Mallawany Nader Kim NK Nader Kim El-Mallawany, Jeremy S. Slone, Michael E. Scheurer, Saeed Ahmed, Gordon E. Schutze, and Parth S

2017 Journal of global oncology PubMed

10. Kaposi Sarcoma Treatment (PDQ®): Health Professional Version

Kaposi Sarcoma Treatment (PDQ®): Health Professional Version Kaposi Sarcoma Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf Warning: The NCBI web site requires JavaScript to function. Search database Search term Search NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): ; 2002 (...) -. Search term Kaposi Sarcoma Treatment (PDQ®) Health Professional Version PDQ Adult Treatment Editorial Board . Published online: July 27, 2018. This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of Kaposi sarcoma. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions. This summary

2018 PDQ - NCI's Comprehensive Cancer Database

11. Clinical and Endoscopic Features of Gastrointestinal Kaposi Sarcoma: A Single-Center Portuguese Experience over the Last Decade (Full text)

Clinical and Endoscopic Features of Gastrointestinal Kaposi Sarcoma: A Single-Center Portuguese Experience over the Last Decade Kaposi sarcoma (KS) is an angioproliferative tumor caused by human herpesvirus 8 (HHV-8). Gastrointestinal (GI) involvement by KS is a rare endoscopic finding, scarcely characterized in the literature.To characterize clinical and endoscopic features of patients with GI KS.This is a single-center retrospective study of GI KS cases confirmed by immunohistochemistry

2017 GE Portuguese journal of gastroenterology PubMed

13. Comment on: 'Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma'. (PubMed)

Comment on: 'Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma'. 30690766 2019 02 25 1365-2230 2019 Jan 28 Clinical and experimental dermatology Clin. Exp. Dermatol. Comment on: 'Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma'. 10.1111/ced.13935 Genovese G G https://orcid.org/0000-0002-7636-958X Unit of Dermatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Department of Pathophysiology

2019 Clinical & Experimental Dermatology

14. Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 associated lymphoproliferative disorders. (PubMed)

Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 associated lymphoproliferative disorders. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 is associated with multicentric Castleman disease (MCD) and primary effusion lymphoma (PEL). In MCD, infected B cells, although polyclonal, express a monotypic immunoglobulin Mλ phenotype, probably through editing toward λ light chain in mature B cells. They are considered to originate from pre-germinal center (GC) naive B cells. Both

2019 Blood

15. PD-L1 expression in tumour microenvironment supports the rationale for immune checkpoint blockade in classic Kaposi's sarcoma. (PubMed)

PD-L1 expression in tumour microenvironment supports the rationale for immune checkpoint blockade in classic Kaposi's sarcoma. Kaposi's sarcoma (KS), a rare human herpesvirus type 8 (HHV8)-associated lymphangioproliferative disorder, is usually skin-limited and slowly progressing.1 However, in the rare cases of locally aggressive or visceral KS refractory to chemotherapy, programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) blockers, a class of immune-checkpoint inhibitors which acts via

2019 Journal of the European Academy of Dermatology and Venereology

16. Management of Kaposi Sarcoma after Solid Organ Transplantation: a European Retrospective Study. (PubMed)

Management of Kaposi Sarcoma after Solid Organ Transplantation: a European Retrospective Study. Systemic therapeutic management of post-transplant Kaposi sarcoma (KS) is mainly based on 3 axes: reduction of immunosuppression, conversion to mammalian target of rapamycin (mTOR) inhibitors and/or chemotherapy.To obtain an overview of clinical strategies about the current treatment of KS.We conducted a multicenter retrospective cohort study including 145 solid organ transplant recipients diagnosed

2019 Journal of American Academy of Dermatology

17. A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma. (PubMed)

A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma. Vascular endothelial growth factor A (VEGF-A) is important in the pathogenesis of Kaposi sarcoma (KS), and bevacizumab has response rate of 31%. We explored the combination of bevacizumab with liposomal doxorubicin in patients with KS.KS patients requiring systemic therapy were enrolled in one of two cohorts. Cohort 1 included patients with human

2019 Clinical Cancer Research

18. Kaposi Sarcoma Herpesvirus Inflammatory Cytokine Syndrome-like Clinical Presentation in Human Immunodeficiency Virus-infected Children in Malawi. (PubMed)

Kaposi Sarcoma Herpesvirus Inflammatory Cytokine Syndrome-like Clinical Presentation in Human Immunodeficiency Virus-infected Children in Malawi. We describe 7 human immunodeficiency virus-infected Malawian children with Kaposi sarcoma who met criteria for Kaposi sarcoma herpesvirus (KSHV) inflammatory cytokine syndrome. Each presented with persistent fevers, bulky lymphadenopathy, massive hepatosplenomegaly, and severe cytopenias. Plasma analyses were performed in 2 patients, both

2019 Clinical Infectious Diseases

19. Randomized controlled trial to evaluate locally sourced two-component compression bandages for HIV-associated Kaposi sarcoma leg lymphedema in western Kenya: The Kenyan Improvised Compression for Kaposi Sarcoma (KICKS) study protocol (Full text)

Randomized controlled trial to evaluate locally sourced two-component compression bandages for HIV-associated Kaposi sarcoma leg lymphedema in western Kenya: The Kenyan Improvised Compression for Kaposi Sarcoma (KICKS) study protocol HIV-associated Kaposi sarcoma (KS), among the most frequent cancers seen in sub-Saharan Africa, is associated with a high prevalence of lymphedema. Lymphedema causes progressive functional impairment marked by swelling, physical discomfort, disfiguring changes (...) , skin hardening from fibrosis, poor wound healing, and recurrent skin infection. While compression therapy is considered a major component of lymphedema management, this intervention has never been evaluated in HIV-associated KS lymphedema.The Kenyan Improvised Compression for Kaposi Sarcoma (KICKS) study is a randomized, controlled trial. Due to variable lymphedema stage, we will use block randomization with a 1:1 allocation to assign participants to one of two groups: "Immediate compression

2018 Contemporary clinical trials communications PubMed

20. Kaposi Sarcoma Treatment (PDQ®): Patient Version

Kaposi Sarcoma Treatment (PDQ®): Patient Version Kaposi Sarcoma Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf Warning: The NCBI web site requires JavaScript to function. Search database Search term Search NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): ; 2002-. Search (...) term Kaposi Sarcoma Treatment (PDQ®) Patient Version PDQ Adult Treatment Editorial Board . Published online: October 4, 2018. Created: December 8, 2006 . This PDQ cancer information summary has current information about the treatment of Kaposi sarcoma. It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health care. Editorial Boards write the PDQ cancer information summaries and keep them up to date

2017 PDQ - NCI's Comprehensive Cancer Database

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>